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Introduction: Although the value of peer review is increasingly rec-
ognized, there is little research documenting its impact in the setting 
of stereotactic body radiation therapy (SBRT) for lung cancer. This 
study determines the dosimetric effect of peer review of tumor and 
normal tissue contouring in lung SBRT planning.
Methods: Forty anonymized lung SBRT plans were retrospectively 
evaluated post treatment. Each plan was independently reviewed 
by two to three radiation oncologists using established institutional 
guidelines. For each structure, reviewers recorded recommenda-
tions for “no change,” “minor change,” “major change,” or “missing 
contour” and provided a modified or new contour as needed. Dose–
volume histograms were analyzed for dosimetric violations.
Results: Among 472 contoured structures evaluated, recommenda-
tions from peer review were 107 major change (23%), 176 minor 
change (37%), 157 no change (33%), and 32 missing (7%). Common 
major changes involved the skin (n = 20), heart (n = 18), and 
proximal bronchial tree (n = 15). Dose constraints were not achieved 
for 25 new or recontoured structures (5%), of which 17 involved the 
planning target volume (PTV). Among cases with PTV violations, 
the mean prescription dose coverage to the modified PTVs was 90%, 
compared with the protocol standard of greater than or equal to 95% 
coverage. The remaining violations involved the ribs (n = 5), spinal 
canal (n = 2), and heart (n = 1).
Conclusions: Peer review of structure contouring resulted in sig-
nificant changes in lung SBRT plans. Recontouring of several plans 
revealed violations of dose limits, most often involving inadequate 
PTV coverage. Peer review, especially of target volume delineation, is 
warranted to improve consistency and quality in lung SBRT planning.
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(J Thorac Oncol. 2014;9: 527–533)
Stereotactic body radiation therapy (SBRT) involves the precise delivery of large radiation doses per fraction to a 
tumor while minimizing normal tissue exposure.1 Compared 
with conventional radiation therapy (RT), SBRT treatment 
volumes are smaller due to the selection of smaller tumors and 
highly conformal dose distributions, allowing for hypofrac-
tionation and dose escalation. Although SBRT can achieve 
higher local control rates compared with conventional RT for 
stage I non–small-cell lung cancer (NSCLC),2–4 precise struc-
ture delineation is crucial, as errors in defining the tumor or 
organs at risk (OARs) could result in adverse consequences 
including suboptimal tumor control or increased treatment 
toxicities.5–7
Target delineation is a large contributor to uncertainty 
in RT planning.7–9 Interobserver variability in contouring lung 
cancer plans has been demonstrated,8,10–13 but its dosimetric 
impact, particularly in the setting of lung SBRT, has not been 
evaluated. With variations in practice patterns with thoracic 
SBRT,4,14 increased international efforts are ongoing to define 
and implement practical and effective quality assurance (QA) 
strategies to meet the demands of increasingly sophisticated 
RT techniques.15 In a 2013 position article from the American 
Society of Radiation Oncologists, Marks et al.16 emphasized 
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the value of peer review in promoting safety and quality of 
care. Although organizations and clinicians endorse the value 
of peer review in RT to improve consistency, workflow, and 
health care costs,15–19 there is little research documenting 
the process and impact of peer review of structure contour-
ing among radiation oncologists, a key step before treatment 
planning.
SBRT as primary treatment for selected patients with 
inoperable, early-stage NSCLC has been employed at the 
British Columbia Cancer Agency (BCCA) since 2009. SBRT 
planning for NSCLC is standardized with a province-wide 
consensus-based protocol containing contouring guidelines, 
dosimetric objectives for target volumes, and critical structure 
dose constraints. At the time of the study, the protocol had 
been used by eight radiation oncologists to treat 60 patients 
with primary lung cancer and peer review of structure con-
touring had not been performed.
The objectives of the current study were to determine: 
(1) the proportion of tumor and normal tissue contours that 
required modification after peer review; (2) the impact of 
peer-reviewed contour modifications on dosimetric violations; 
and (3) whether there was an institutional learning curve.
MATERIALS AND METHODS
Between May 2009 and August 2011, 60 patients 
received lung SBRT for solitary primary NSCLC at three 
BCCA centers. All tumors were pathologically confirmed and 
were located greater than 2 cm away from the proximal bron-
chial tree in all directions. Clinical stages included were T1-3, 
N0, M0, with all tumors less than or equal to 5 cm. The first 20 
patients treated in 2009–2010 and the most recent 20 patients 
treated in 2011 were selected as study subjects. For the 40 
subjects selected for study, contouring was completed by the 
treating radiation oncologist with no formal peer review of 
contours before planning.
The dose prescription was 48 Gy in four fractions. All 
patients underwent computed tomography (CT) planning 
scan, and 32 had four-dimensional (4D)-CT imaging. Positron 
emission tomography imaging, if available, was not coreg-
istered with CT planning scans. Eclipse treatment planning 
software (Varian Medical Systems, Palo Alto, CA) was used 
to create the original plans and to review the plans after peer 
review. Dose calculations were performed using anisotropic 
analytic algorithm with heterogeneity correction enabled.
Two versions of the institutional SBRT lung protocol 
were used during the study period: (1) the May 2008 ver-
sion under which the first 20 cases were planned and (2) the 
November 2010 version under which the last 20 cases were 
planned. The only relevant difference between the two ver-
sions was that in the updated 2010 version, the ribs and great 
vessels were added as OARs requiring delineation. The proto-
col included brief descriptions (2–3 sentences each) on how 
the target volumes and OARs should be delineated. Both ver-
sions had instructions on margin expansion around the gross 
tumor volume in cases where 4D-CT was not available. The 
protocol-specified dose and volume constraints (Table 1) were 
based on the RT Oncology Group 0813 protocol.20
All plans were anonymized of patient and treating 
oncologist identifiers using DICOM Scrubber software and 
distributed to 11 radiation oncologist reviewers. Reviewers 
were based in four regional BCCA centers, all with cur-
rent experience in NSCLC treatment. Reviewers were not 
assigned to any of the plans they had originally treated and 
were blinded to any previous reviews. All peer reviews were 
performed using contouring guidelines from the 2010 institu-
tional protocol.
For each plan, the following contours were reviewed 
independently by two radiation oncologists: gross tumor vol-
ume, internal target volume if 4D-CT was available, planning 
target volume (PTV), proximal trachea, proximal bronchial 
TABLE 1.  Dose Constraints from BCCA Lung SBRT Protocol
Structure Maximum Point Dose Volume Volume Dose Maximum (Gy) End Point
Spinal cord 21 Gy <0.35 cc 16.8 Myelitis
<1.2 cc 11
Lung GTV NA <20% 20 Pneumonitis
>1500 cc <11.6
>1000 cc <12
Heart 33 Gy <15 cc 28 Pericarditis
Proximal trachea 33 Gy <4 cc 15.6 Stenosis/fistula
Proximal bronchial tree 33 Gy <4 cc 15.6 Stenosis/fistula
Brachial plexus 27 Gy <3 cc 27 Neuropathy
Esophagus 30 Gy <5 cc 18.8 Stenosis/fistula
Great vessels 49 Gy <10 cc 43 Aneurysm
Ribs 40 Gy <1 cc 32 Pain/fracture
Skin 30 Gy <10 cc 28 Ulceration
Dose Volume
PTV Prescription dose >95%
90% of prescription dose >99%
BCCA, British Columbia Cancer Agency; SBRT, stereotactic body radiation therapy; GTV, gross tumor volume; NA, not applicable; PTV, planning target volume.
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tree, esophagus, lungs, heart, great vessels, spinal canal, 
brachial plexus, ribs, and skin. For each structure, review-
ers examined the original contours and assigned one of the 
following scores: “major change required,” defined as origi-
nal contour unacceptable; “minor change required,” defined 
as original contour still acceptable; “no change required”; 
or “missing contour.” If the scoring was discrepant between 
two reviewers (one selected major change, whereas the other 
selected minor change or no change), the case was distributed 
to a third oncologist for additional peer review. A contour was 
defined as “major change required” if this was agreed upon 
by two reviewers (Table 2). When a peer reviewer advised a 
change or found that the contour was missing, he or she pro-
vided a new contour and the reason(s) for any changes.
Dose–volume histograms (DVH), based on the new 
contours after peer review and the previously delivered plan, 
were assessed for dosimetric violations. To determine whether 
a violation existed, the given dose or volume measurements of 
all modified versions of the contour were averaged and com-
pared with the corresponding protocol constraint. For example, 
one of the protocol stipulations was that greater than or equal 
to 95% of the PTV should achieve the prescription dose. To 
check whether this stipulation was violated, we determined the 
percentage volume of each reviewer’s version of the PTV that 
would receive the prescription dose, assuming that the original 
plan was applied; if the average of these values was less than 
95%, this was considered a PTV dosimetric violation.
For each PTV and non-rib OAR that had a dosimetric 
violation (as defined previously) after peer-review contour 
modification, the volume of all contoured versions of the 
structure was recorded, and the conformity index (CI) was 
calculated. The CI of a given structure was defined as the ratio 
of the overlapping volume common for all versions of delinea-
tion (including the original) to the encompassing total volume 
of all versions of delineation.21 A CI of 1 indicates perfectly 
overlapping volumes. A CI of 0.5 indicates that the observers 
agree on 50% of the total delineated volume.
Statistical Analysis
The sample size of 40 plans was chosen to provide 
an estimated SE of ±2% on an anticipated minor/major 
modification prevalence of 15%. Descriptive statistics were 
used to report the proportions of contours within each peer 
assessment scoring category, the proportions of new con-
tours resulting in DVH violations, the DVH characteristics 
of these violations, and the volume measurements and con-
formity indices of the tumor. In the early versus late cohort, 
comparisons in the percentage of major changes, minor 
changes, missing contours, and PTV violations were per-
formed using independent t testing and Pearson chi-square 
testing. One-way analysis of variance was used for compari-
son among treating radiation oncologists in the percentage 
of peer-review scores and PTV violations. All analyses were 
performed using Microsoft Excel 2008 (Santa Rosa, CA) and 
SPSS software, version 14.0 (Chicago, IL). The study was 
approved by the University of British Columbia, BC Cancer 
Agency Research Ethics Board.
RESULTS
The 40 subjects were treated by eight radiation oncolo-
gists at three regional cancer centers. A total of 512 contours 
were reviewed. Of these, the ribs and great vessels of the first 
20 plans were excluded, as the 2008 protocol did not mandate 
contouring of these structures. Among the remaining 472 con-
tours, 120 (25%) required a third review to resolve discrepant 
scores between the first two reviews.
Proportions of Contours 
Modified on Peer Review
Final recommendations from peer review were 107 
major changes (23%), 176 minor changes (37%), 157 no 
changes (33%), and 32 missing (7%). All 40 plans had at least 
one recommendation for modification. There were 32 plans 
(80%) with at least one major change recommended. Table 3 
displays the distribution of final recommendations per struc-
ture and the most common reasons for changes. An example 
of a reason that was more often provided for major rather than 
minor change was “spinal cord contoured instead of the spinal 
canal.” An example that was associated more often with minor 
change was “great vessels included in the heart contour.” The 
contours most frequently modified were the skin, heart, and 
proximal bronchial tree. Of the 40 PTVs, there were seven 
major changes and 17 minor changes.
Impact of Peer-Reviewed Contour 
Modifications on Dosimetric Violations
Overall, 25 of 472 contoured structures (5%) had dosi-
metric violations when original plans were reapplied to the 
modified contours. The structures associated with dosimetric 
violations were the PTV (n = 17), ribs (n = 5), spinal canal 
(n = 2), and heart (n = 1). Among the 17 plans with PTV dosi-
metric violations, the mean volume of the recontoured PTVs 
covered by the prescription dose was 90% (range, 75%–95%; 
SD, 5.5%), compared with the protocol standard of greater 
than or equal to 95%. The mean volume receiving 90% of the 
prescription dose was 95% (range, 82%–100%; SD 4.6%), 
compared with the protocol standard of greater than or equal 
to 99%. Nine of the 17 violations deviated from the protocol 
TABLE 2.  System for Determining the Overall 
Recommendation for Each Contour
First Reviewa Second Reviewa Third Review
Final 
Recommendation
Major change Major change NA Major change
Major change No change or 
minor change
Major change Major change
Major change No change or 
minor change
Minor change Minor change
Minor change Minor change NA Minor change
Minor change No change NA Minor change
No change No change NA No change
Missing Missing NA Missing
aFirst review and second review are interchangeable.
NA, not applicable.
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standard by greater than or equal to 3%. On review of the orig-
inal PTV contours, all dose constraints had been achieved. For 
the 17 PTV violations, the reviewers’ reasons for modifying 
the original PTV are reported in Table 4.
In the two cases with spinal canal violations, the dose–
volume constraint that was exceeded was V
11Gy
 (5.4 and 5.7 cc), 
while the maximum dose and V
16.8Gy
 were within tolerance. 
Nevertheless, on review of the original contours, V
11Gy
 
had already been exceeded to a similar extent (5.1 and 5.6 
cc). Similarly, among five cases with rib violations, the 
violations were due to exceeding the V
32Gy
 (average, 3.1 
cc; range, 1.1–7.3 cc; SD, 2.5 cc), but similar preexisting 
V
32Gy
 violations were already present with the original rib 
contours (average, 3.1 cc; range, 1.1–7.5 cc; SD, 2.6 cc). 
Maximum dose tolerance was met in all original and modi-
fied rib contours. On the single plan with the heart dose 
violation, the maximum dose to the two revised versions of 
the heart contour was 53.4 and 16.1 Gy (average, 34.8 Gy), 
compared with a maximum dose of 16.4 Gy to the original 
heart contour.
TABLE 3.  Distribution of Peer-Review Recommendations for 472 Contoured Structures and Reasons for Recommended 
Changes
Structure
Major Change, 
n (%)
Minor Change, 
n (%)
No Change, 
n (%)
Missing, 
n (%)
Three Most Frequently Reported Reasons for  
Changes (No. of Plans)
Skin (n = 40) 20 (50) 8 (20) 10 (25) 2 (5) Axillary fold not contoured (n = 28)
Heart (n = 40) 18 (45) 18 (45) 4 (10) 0 (0) Not extended superiorly enough (n = 19)
Great vessels included (n = 8)
Pericardium not included (n = 4)
Proximal bronchial tree 
(n = 40)
15 (38) 16 (40) 7 (18) 2 (5) Cartilage not contoured (n = 9)
Contralateral side not contoured (n = 6)
Combined with proximal trachea (n = 4)
Spinal canal (n = 40) 12 (30) 14 (35) 14 (35) 0 (0) Not extended superiorly and/or inferiorly enough (n = 10)
Spinal cord contoured instead of canal (n = 8)
Not extended radially enough to cover all of canal (n = 4)
Proximal trachea (n = 40) 8 (20) 14 (35) 14 (35) 4 (10) Cartilage not contoured (n = 8)
Not extended superiorly enough (n = 4)
Combined structure with proximal bronchial tree (n = 4)
PTV (n = 40) 7 (18) 17 (43) 16 (40) 0 (0) Change in GTV contour (n = 5)
ITV not contoured even though 4D-CT available (but GTV 
contoured) (n = 4)
GTV not contoured (but ITV contoured) (n = 3)
Great vessels (n = 20) 4 (20) 7 (35) 9 (45) 0 (0) Ipsilateral great vessels not contoured (n =5)
Heart and/or contralateral great vessels included (n = 5)
Contour not extended superiorly or inferiorly enough (n = 3)
GTV (n = 40) 7 (18) 11 (28) 8 (20) 14 (35) Contoured based on MIP instead of regular CT (n = 4)
Inaccurate contour (n = 3)
Included some small vessels (n = 1)
Brachial plexus (n = 40) 6 (15) 20 (50) 12 (30) 2 (5) Contour not extended distally enough (n = 5)
Contralateral side not contoured (n = 5)
Contour extended too superiorly (n = 2)
Ribs (n = 20) 4 (20) 8 (40) 7 (35) 1 (5) Ribs not completely contoured within PTV + 5 cm (n = 10)
Chest wall included (n = 2)
ITV (n = 32) 3 (9) 13 (41) 11 (34) 5 (16) Contour too tight (n = 1)
Not extended inferiorly enough (n = 1)
Not extended inferiorly and superiorly enough (n = 1)
Esophagus (n = 40) 2 (5) 19 (48) 17 (43) 2 (5) Contour not extended superiorly and/or inferiorly enough (n = 6)
Missed contouring a few slices (n = 2)
Slight overlap with trachea and proximal bronchial tree (n = 1)
Lung (n = 40) 1 (3) 11 (28) 28 (70) 0 (0) GTV/ITV not excluded (n = 7)
Liver not excluded (n = 2)
PTV excluded instead of GTV/ITV (n = 2)
Total 107 (23) 176 (37) 157 (33) 32 (7)
PTV, planning target volume; GTV, gross tumor volume; ITV, internal target volume; 4D-CT, four-dimensional computed tomography; MIP, maximum intensity projection.
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For the 17 PTVs and three non-rib OARs with dosimet-
ric violations, the volume of the original contour and review-
ers’ contours, as well as conformity indices, are displayed in 
Table 5. The median CI was 74%, with a range from 29% to 
93%, and a SD of 16%.
Early versus Later Cohort
Compared with the later cohort, a higher proportion of 
contours in the early cohort required major change (28% ver-
sus 18%, p = 0.076) and a lower proportion required no change 
(20% versus 46%, p < 0.001). There was no statistically sig-
nificant difference in the proportions of contours that required 
minor change (34% versus 40%, p = 0.27) or that were missing 
(8% versus 5%, p = 0.19). There was also no significant differ-
ence in the number of PTV violations among the early com-
pared with later cohort (n = 9 versus n = 8, p = 0.76).
Comparison of Treating Radiation Oncologists
Per treating radiation oncologist, the percentage of con-
tours requiring major change ranged from 0% to 42%; minor 
change, 15% to 50%; no change, 25% to 58%; and missing, 
0% to 8%, whereas PTV violations ranged from 0% to 46%. 
Only the proportion of contours requiring minor change was 
statistically different between oncologists (p = 0.002).
DISCUSSION
The value of interdisciplinary peer review is being 
increasingly recognized in the modern era of sophisticated RT 
techniques.16–18,22 The current study is among the first to focus 
on the effect of peer review of structure contouring by radia-
tion oncologists in the setting of NSCLC SBRT planning. The 
peer audit and feedback performed in this study resulted in a 
large number of changes in contours, some of which signifi-
cantly impacted dosimetric outcomes.
Previous studies have reported wide interobserver vari-
ability in delineation of target volume and OARs in  non-SBRT 
TABLE 4.  Reason for PTV Changes for the 17 PTV Violations
Reason for PTV Change No. of Cases
ITV not contoured even though 4D-CT available 4
Inadequate coverage of GTV or ITV 3
Inadequate margin from ITV to PTV 1
Not specified 9
PTV, planning target volume; ITV, internal target volume; 4D-CT, four-dimensional 
computed tomography; GTV, gross tumor volume.
TABLE 5.  Volumes and Conformity Index of Delineation of Structures for Which There Was a Dosimetric Violationa
Structure Advised Change
Volume of Contoured Structure (cm3)
Encompassing 
Total Delineated 
Volume of All 
Contoured 
Versions of the 
Structureb (cm3)
Overlapping 
Volume 
Common to 
All Versions 
of Contoured 
Structurec (cm3)
Conformity 
Index (i.e., 
Overlapping 
Volume/ 
Encompassing 
Total Delineated 
Volume) (%)Original Reviewer #1 Reviewer #2 Reviewer #3
Planning target 
volume
Major 14.8 15.3 18.6 17.0 18.7 14.0 75
40.4 44.6 40.9 NA 45.6 38.7 85
74.0 86.6 74.0 82.2 94.3 71.8 76
48.7 46.1 65.5 73.5 85.8 41.5 48
69.5 68.8 56.5 60.7 82.5 49.9 60
76.6 70.7 79.0 NA 83.3 66.2 79
Minor 20.1 21.4 12.5 NA 21.6 12.5 58
35.2 35.8 35.2 NA 38.8 31.7 82
33.4 34.0 37.4 NA 38.7 30.4 79
26.0 32.6 27.8 26.9 33.4 24.6 74
42.9 42.9 43.2 NA 44.5 41.6 93
35.6 55.9 35.6 NA 57.0 34.4 60
13.2 14.4 13.2 NA 14.4 13.2 91
28.8 28.8 38.9 32.2 40.1 27.5 69
47.2 56.8 50.8 42.7 72.4 40.1 64
26.9 25.8 29.1 NA 29.6 25.6 86
15.2 15.2 12.6 15.9 16.9 11.9 70
Spinal canal Major 16.6 42.6 53.6 36.5 56.3 16.2 29
97.6 116.2 115.1 NA 120.6 97.0 80
Heart 751.8 1252.9 1125.6 NA 1339.2 747.1 56
aSee sixth paragraph of Materials and Methods for definition of dosimetric violation.
bUsing Boolean operators, encompassing total delineated volume = ([original contour OR reviewer #1’s contour] OR reviewer #2’s contour) OR reviewer #3’s contour.
cUsing Boolean operators, overlapping volume = ([original contour AND reviewer #1’s contour] AND reviewer #2’s contour) AND reviewer #3’s contour.
NA, not applicable because a third review was not required.
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lung cancer planning.8,11,13,23–25 A recent study suggested that 
delineation variation may be smaller in peripheral lung tumors 
referred for SBRT in a single-institutional setting.26 In all 
these studies, participants delineated structures on a com-
mon radiological data set, and interobserver variation was 
quantified using various parameters involving distribution 
of volumes, overlap between contoured volumes, and statis-
tical measures of agreement.8,11,13,23–25 Previous studies have 
not investigated whether contour variations had a meaningful 
influence on dose distribution. In contrast, the current analy-
sis confirmed the prevalence of contouring variations but also 
identified the number and reasons for recommended changes 
and their dosimetric impacts. Despite the use of a standard-
ized protocol, significant contouring variations existed among 
practicing lung radiation oncologists. Many recommenda-
tions for contour modification were based on nonadherence or 
differences in interpretation of contouring guidelines. These 
findings highlight the importance of detailed demonstration 
of contouring guidelines and ongoing peer review to stimulate 
discussions to identify common sources of discrepancy.
Among the eight treating radiation oncologists in the 
current study, a significant difference was observed only in 
the percentage of minor changes recommended to each oncol-
ogist, but the clinical implication of this finding is unclear 
given that the proportions of PTV violations, missing con-
tours, contours requiring no change, and contours requiring 
major change were not statistically different. Compared with 
the early plans, the later plans had fewer recommended major 
changes, and a significantly greater proportion of contours that 
required no change suggesting an institutional learning curve 
effect. An important consideration is that the small number 
(average 2–3) of cases per treating radiation oncologist in 
the early period may have been inadequate to overcome the 
expected individual learning curve. Consequently, the insti-
tutional learning curve may not have plateaued by the end of 
the early period, and thus, the true magnitude of the learning 
curve effect could be larger than demonstrated by this study. 
This underscores the necessity of rigorous peer review dur-
ing early stages of protocol implementation, to allow prompt 
detection and troubleshooting of contouring discrepancies.
Examination of dose distributions of the reviewers’ 
new contours superimposed on the previously treated plans 
is a unique and informative aspect of this study. The con-
tour changes that resulted in protocol violations most often 
involved the PTV, whereas changes to OARs seldom made 
such an impact. In the rib and spinal canal violations, vol-
ume constraints of the original contours existed even before 
reviewer modification. Rather than representing oversights, 
these original violations likely represent an informed accep-
tance of the risks of exceeding constraints, in the interest of 
ensuring adequate dose coverage to the target volume. On the 
other hand, dose violations affecting 17 of the 24 modified 
PTVs are of greater clinical concern. Of these PTV violations, 
the interobserver CI ranged widely from 48% to 93%, and the 
volume covered by the prescription dose ranged from 75% to 
94%, compared with the protocol standard of 95%. Although 
a degree of interobserver variation should be accounted for by 
the margin used to create the PTV,27 it is likely inadequate for 
the large magnitude of contouring variability and its dosimetric 
impact demonstrated in this study, suggesting that an improve-
ment in consistency is required. Had these volumes been peer 
reviewed before treatment, group discussion may have ensured 
a more optimal, consensus-derived target delineation.
This study should be interpreted in the context of its 
strengths and limitations. As the design is focused on peer 
review and modification of previously contoured structures, 
the results are not directly comparable to studies in which 
multiple observers delineated structures from a blank slate. In 
addition, as there is no gold standard contour, it is not possible 
to conclude that the contours generated by reviewers were 
more accurate compared with those generated by the treat-
ing oncologist. A further limitation is that the clinical impact 
of planning violations including tumor response and normal 
tissue toxicity was not evaluated. Despite these limitations, 
the current study is of value in documenting that peer review 
among radiation oncologists in auditing and modifying con-
tours for NSCLC SBRT planning is feasible and that modified 
contours have dosimetric impact on SBRT plans.
Although there is consensus that peer review should 
be integrated into routine practice to promote safety and 
enhance care and education,16–18,28 standardized processes 
for  peer-review quality improvement are needed. In a sur-
vey of 14 centers in a Canadian province, Brundage et al.18 
reported that detection of errors and improvement in plan-
ning processes were the highest rated perceived benefits of 
peer review. Although there were variations in peer-review 
practices among centers, 93% reported plans to expand 
peer-review activities. In keeping with these findings, QA 
rounds for NSCLC SBRT have been established at our insti-
tution since August 2011. These rounds currently consist of 
monthly hour-long province-wide meetings in which three to 
six cases are reviewed by radiation oncologists, dosimetrists, 
and physicists. Selected challenging cases are presented, often 
prompting insightful and productive discussions, but the short 
available time limits the opportunity to review all cases and all 
contours in detail.
In the current study, the identification of contouring 
variations with dosimetric impact on peer review supports the 
implementation of an expanded, more rigorous peer review 
QA process for NSCLC SBRT and research evaluating the 
use of automated training tools to improve contouring con-
sistency.29,30 Real-time review of target volume delineation 
should be prioritized, as discrepancies in PTV delineation has 
the greatest risk of causing dose–volume violations. Hence, 
in addition to QA rounds, our institution is now implement-
ing a process in which the PTV for all NSCLC SBRT plans 
is reviewed by a second radiation oncologist before treatment. 
Second, the specific reasons for change stemming from peer 
review reported in this study have formed the basis for inter-
active group dialog and feedback and have led to the devel-
opment of a clearer, more detailed contouring atlas at our 
institution. Although peer review and improving contouring 
guidelines are likely to decrease interobserver consistency, 
one might question whether these strategies are sufficient 
in working toward an optimal, standard procedure level of 
contouring. To this end, employing the expertise of diagnos-
tic radiologists in education and review of contouring is an 
approach that should be further explored.
533Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 4, April 2014 Volume Delineation in SBRT Planning
CONCLUSIONS
Peer review of target and normal structure contouring 
is feasible and resulted in significant changes for SBRT plans 
for patients with NSCLC. Several recontoured plans violated 
dose limits, most often involving inadequate PTV coverage. A 
smaller proportion of changes recommended on peer review 
in the later versus earlier plans suggested an institutional 
learning curve. Peer review QA, particularly in target volume 
delineation, is warranted as a starting point to improve consis-
tency and quality in SBRT planning for patients with NSCLC.
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